Abstract
The SARS-CoV-2 pandemic has been a global challenge. In times of difficulty such as those that have recently arisen, research is even more necessary to advance in the diagnosis and treatment of different pathologies. Using the extensive development of the media, this year the American Congress of Cardiology was held from March 28 to 30 in a virtual format, allowing professionals from around the world to access multiple scientific activities with the same level of excellence as in face-to-face sessions.We will make a brief summary of some of the main scientific papers presented: Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response after Percutaneous Coronary Intervention: TAILOR–PCI. Rivaroxaban in Peripheral Artery Disease after Revascularization: VOYAGER PAD trial Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction: VICTORIA Study Group. The Evolut Low Risk Bicuspid Study. PARTNER 3. Two-year clinical and echocardiographic outcomes. Ticagrelor with and without Aspirin in Acute Coronary Syndrome After PCI: the TICO Trial. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer: Caravaggio trial. Ten-year Outcomes After Drug-eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease: Extended Follow Up of the PRECOMBAT Trial. Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation: POPular TAVI.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
